Prevention of experimental Haemophilus ducreyi infection: A randomized, controlled clinical trial

Alice C. Thornton, Edward M. O'Mara, Suellyn J. Sorensen, Thomas J. Hiltke, Kate Fortney, Barry Katz, Ronald E. Shoup, Antoinette F. Hood, Stanley M. Spinola

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Human subjects were infected with Haemophilus ducreyi. All subjects developed papules and were randomized to treatment with a single dose of azithromycin (1 g) or ciprofloxacin (500 mg). At weekly intervals, volunteers were reinoculated with H. ducreyi, and drug concentrations were measured in peripheral blood mononuclear cells (PBMC). When papules developed, the subjects were treated with antibiotics and dismissed from the study. Eight of the ciprofloxacin-treated subjects developed papules 1 week after the initial treatment, and the ninth subject developed disease 2 weeks after treatment. The 9 azithromycin-treated subjects developed papules 4-10 weeks (mean, 6.8) after the initial treatment (P < .001). Azithromycin was detected in PBMC for 3-6 weeks (mean, 4). Pre- and posttreatment lesions had histology typical of experimental chancroid or were culture positive. Azithromycin prevents experimental chancroid for nearly 2 months. These findings have implications for strategies to prevent chancroid.

Original languageEnglish
Pages (from-to)1608-1613
Number of pages6
JournalJournal of Infectious Diseases
Volume177
Issue number6
StatePublished - 1998

Fingerprint

Haemophilus ducreyi
Haemophilus Infections
Azithromycin
Chancroid
Randomized Controlled Trials
Ciprofloxacin
Blood Cells
Therapeutics
Volunteers
Histology
Anti-Bacterial Agents
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Thornton, A. C., O'Mara, E. M., Sorensen, S. J., Hiltke, T. J., Fortney, K., Katz, B., ... Spinola, S. M. (1998). Prevention of experimental Haemophilus ducreyi infection: A randomized, controlled clinical trial. Journal of Infectious Diseases, 177(6), 1608-1613.

Prevention of experimental Haemophilus ducreyi infection : A randomized, controlled clinical trial. / Thornton, Alice C.; O'Mara, Edward M.; Sorensen, Suellyn J.; Hiltke, Thomas J.; Fortney, Kate; Katz, Barry; Shoup, Ronald E.; Hood, Antoinette F.; Spinola, Stanley M.

In: Journal of Infectious Diseases, Vol. 177, No. 6, 1998, p. 1608-1613.

Research output: Contribution to journalArticle

Thornton, AC, O'Mara, EM, Sorensen, SJ, Hiltke, TJ, Fortney, K, Katz, B, Shoup, RE, Hood, AF & Spinola, SM 1998, 'Prevention of experimental Haemophilus ducreyi infection: A randomized, controlled clinical trial', Journal of Infectious Diseases, vol. 177, no. 6, pp. 1608-1613.
Thornton AC, O'Mara EM, Sorensen SJ, Hiltke TJ, Fortney K, Katz B et al. Prevention of experimental Haemophilus ducreyi infection: A randomized, controlled clinical trial. Journal of Infectious Diseases. 1998;177(6):1608-1613.
Thornton, Alice C. ; O'Mara, Edward M. ; Sorensen, Suellyn J. ; Hiltke, Thomas J. ; Fortney, Kate ; Katz, Barry ; Shoup, Ronald E. ; Hood, Antoinette F. ; Spinola, Stanley M. / Prevention of experimental Haemophilus ducreyi infection : A randomized, controlled clinical trial. In: Journal of Infectious Diseases. 1998 ; Vol. 177, No. 6. pp. 1608-1613.
@article{49282964c15c446496aa2e77ef338ee4,
title = "Prevention of experimental Haemophilus ducreyi infection: A randomized, controlled clinical trial",
abstract = "Human subjects were infected with Haemophilus ducreyi. All subjects developed papules and were randomized to treatment with a single dose of azithromycin (1 g) or ciprofloxacin (500 mg). At weekly intervals, volunteers were reinoculated with H. ducreyi, and drug concentrations were measured in peripheral blood mononuclear cells (PBMC). When papules developed, the subjects were treated with antibiotics and dismissed from the study. Eight of the ciprofloxacin-treated subjects developed papules 1 week after the initial treatment, and the ninth subject developed disease 2 weeks after treatment. The 9 azithromycin-treated subjects developed papules 4-10 weeks (mean, 6.8) after the initial treatment (P < .001). Azithromycin was detected in PBMC for 3-6 weeks (mean, 4). Pre- and posttreatment lesions had histology typical of experimental chancroid or were culture positive. Azithromycin prevents experimental chancroid for nearly 2 months. These findings have implications for strategies to prevent chancroid.",
author = "Thornton, {Alice C.} and O'Mara, {Edward M.} and Sorensen, {Suellyn J.} and Hiltke, {Thomas J.} and Kate Fortney and Barry Katz and Shoup, {Ronald E.} and Hood, {Antoinette F.} and Spinola, {Stanley M.}",
year = "1998",
language = "English",
volume = "177",
pages = "1608--1613",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Prevention of experimental Haemophilus ducreyi infection

T2 - A randomized, controlled clinical trial

AU - Thornton, Alice C.

AU - O'Mara, Edward M.

AU - Sorensen, Suellyn J.

AU - Hiltke, Thomas J.

AU - Fortney, Kate

AU - Katz, Barry

AU - Shoup, Ronald E.

AU - Hood, Antoinette F.

AU - Spinola, Stanley M.

PY - 1998

Y1 - 1998

N2 - Human subjects were infected with Haemophilus ducreyi. All subjects developed papules and were randomized to treatment with a single dose of azithromycin (1 g) or ciprofloxacin (500 mg). At weekly intervals, volunteers were reinoculated with H. ducreyi, and drug concentrations were measured in peripheral blood mononuclear cells (PBMC). When papules developed, the subjects were treated with antibiotics and dismissed from the study. Eight of the ciprofloxacin-treated subjects developed papules 1 week after the initial treatment, and the ninth subject developed disease 2 weeks after treatment. The 9 azithromycin-treated subjects developed papules 4-10 weeks (mean, 6.8) after the initial treatment (P < .001). Azithromycin was detected in PBMC for 3-6 weeks (mean, 4). Pre- and posttreatment lesions had histology typical of experimental chancroid or were culture positive. Azithromycin prevents experimental chancroid for nearly 2 months. These findings have implications for strategies to prevent chancroid.

AB - Human subjects were infected with Haemophilus ducreyi. All subjects developed papules and were randomized to treatment with a single dose of azithromycin (1 g) or ciprofloxacin (500 mg). At weekly intervals, volunteers were reinoculated with H. ducreyi, and drug concentrations were measured in peripheral blood mononuclear cells (PBMC). When papules developed, the subjects were treated with antibiotics and dismissed from the study. Eight of the ciprofloxacin-treated subjects developed papules 1 week after the initial treatment, and the ninth subject developed disease 2 weeks after treatment. The 9 azithromycin-treated subjects developed papules 4-10 weeks (mean, 6.8) after the initial treatment (P < .001). Azithromycin was detected in PBMC for 3-6 weeks (mean, 4). Pre- and posttreatment lesions had histology typical of experimental chancroid or were culture positive. Azithromycin prevents experimental chancroid for nearly 2 months. These findings have implications for strategies to prevent chancroid.

UR - http://www.scopus.com/inward/record.url?scp=0031748517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031748517&partnerID=8YFLogxK

M3 - Article

C2 - 9607840

AN - SCOPUS:0031748517

VL - 177

SP - 1608

EP - 1613

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 6

ER -